An anti-cancer drug developed by Kazakh scientists has successfully passed two initial phases of clinical trials, as announced by the Vice President of the National Academy of Sciences Dos Sarbassov. According to the biology professor, the drug can stabilize and improve a patient’s condition, halting disease progression even in its advanced stages. It should be noted that scientists from the Kazakh Institute of Oncology and Radiology are conducting clinical trials of the anti-cancer drug. The injection dose for patients has now been doubled, with medical experts confirming the absence of toxicity. The drug already holds an international patent.
«Five patients showed stabilization, meaning the tumor did not grow. In one patient, the tumor shrank by 30 percent, which is a significant effect, even with a small dose. We were very pleased with this data, but this is only the initial effect. It suggests that the drug may work, but we need to see it through to the end,» noted Dos Sarbassov, biologist and Nazarbayev University professor.
Related Articles
